Neurotrope, which is the last company running trials in moderate-to-severe Alzheimer's patients, may be worth a look, going into late-summer readout:
Neurotrope approaches Alzheimer's as a disease of synaptic loss (starting in the hippocampus). Their drug Bryostatin regrows synapses, clears Amyloid-Beta and Tau, and is neuro-protective.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.